Forbion European Acquisition Corp.
Status: Closed Deal
U=S+W/3
W=S@11.50
| IPO Proceeds, $M | $126.50M |
|---|---|
| IPO Date | Dec 10, 2021 |
| CEO | Jasper Bos |
| Left Lead | UBS |
| IPO Cash in Trust | 102.5% |
| SPAC Tenor | 18 + 3 + 3 |
| IPO Sector | Healthcare ▶ |
| IPO Geography | Europe |
| Target Company | enGene |
| Deal Announced | May 17, 2023 |
| Deal Size, $M | $150.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Oct 24, 2023 |
| Amendment Vote | TBD |
| Closing Date | Oct 31, 2023 |
Formerly FRBN
ENGN
ENGNW
| Price | $8.53 |
|---|---|
| Last closing price | $8.43 |
| H/L, today | $8.32 / $9.20 |
| H/L, 52-week | $17.89 / $43.00 |
| Volume, today | 1,200,313 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.